Bio-Rad Laboratories, Inc. $BIO Holdings Lifted by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 4.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,753 shares of the medical research company’s stock after acquiring an additional 4,351 shares during the period. Envestnet Asset Management Inc. owned about 0.40% of Bio-Rad Laboratories worth $30,213,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of BIO. Allianz Asset Management GmbH grew its position in Bio-Rad Laboratories by 22.7% during the third quarter. Allianz Asset Management GmbH now owns 66,549 shares of the medical research company’s stock valued at $18,660,000 after purchasing an additional 12,310 shares in the last quarter. Atlantic Union Bankshares Corp bought a new stake in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $1,149,000. Jones Financial Companies Lllp grew its position in Bio-Rad Laboratories by 6.7% in the third quarter. Jones Financial Companies Lllp now owns 1,276 shares of the medical research company’s stock worth $346,000 after acquiring an additional 80 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 40 shares during the last quarter. Finally, AlphaQuest LLC bought a new position in shares of Bio-Rad Laboratories in the 3rd quarter valued at approximately $337,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories News Roundup

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Q4 revenue grew year-over-year (~3.9%), showing ongoing top-line demand in the business despite tougher comps — a constructive read for revenue momentum. MarketBeat Q4 summary
• Neutral Sentiment: The company published its earnings call transcript, press release and slide deck — useful for investors to assess management’s explanation of results, margin drivers and any one-time items. Review the call for color on profitability and outlook. Earnings Call Transcript
• Neutral Sentiment: Management issued FY2026 revenue guidance centered near $2.6 billion (roughly in line with consensus), but the EPS guidance in the release was unclear/unspecified in headlines — that ambiguity likely amplified investor uncertainty. (See company release for detail.) Press Release
• Negative Sentiment: Reported EPS of $2.51 missed the consensus of $2.57 and declined from $2.90 a year ago — the EPS shortfall is the primary near-term negative catalyst. Zacks: Earnings Miss
• Negative Sentiment: News coverage notes the stock “tumbled” after the print; investors are reacting to the EPS miss, margin pressure (reported negative net margin) and unclear EPS outlook. That selloff drove higher-than-normal intraday volume. Investing.com: Shares Tumble

Bio-Rad Laboratories Trading Down 0.7%

Shares of Bio-Rad Laboratories stock opened at $291.67 on Friday. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12. The firm has a market capitalization of $7.87 billion, a PE ratio of -12.00 and a beta of 1.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.44 and a quick ratio of 3.94. The company’s fifty day moving average price is $306.69 and its two-hundred day moving average price is $300.79.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%. The business had revenue of $693.20 million for the quarter, compared to analyst estimates of $694.64 million. During the same quarter last year, the firm posted $2.90 earnings per share. Bio-Rad Laboratories’s revenue was up 3.9% on a year-over-year basis. On average, analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

BIO has been the topic of several analyst reports. Citigroup increased their price target on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wall Street Zen raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.